Clascoterone

Base Information

• Chemical Name: Clascoterone
• CAS No.: 19608-29-8
• Molecular Formula: C24H34O5
• Molecular Weight: 402.531
• UNII: XN7MM8XG2M
• ChEMBL ID: CHEMBL3590187
• DSSTox Substance ID: DTXSID10471883
• Metabolomics Workbench ID: 153477
• NCI Thesaurus Code: C169855
• Nikkaji Number: J2.604.270D
• RXCUI: 2474340
• Wikidata: Q27293917
• Wikipedia: Clascoterone
• Mol file: 19608-29-8.mol

Synonyms:CB-03-01;Clascoterone;cortexolone 17alpha-propionate;winlevi

Chemical Property of Clascoterone

Chemical Property:

• Boiling Point: 538.898 °C at 760 mmHg
• PKA: 12.98±0.10(Predicted)
• Flash Point: 179.292 °C
• PSA: 80.67000
• Density: 1.193 g/cm³
• LogP: 3.77170
• Solubility.: Soluble in DMSO
• XLogP3: 3.9
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 5
• Exact Mass: 402.24062418
• Heavy Atom Count: 29
• Complexity: 769

Purity/Quality:

98%,99%, ^*data from raw suppliers

CB-03-01 99% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)C(=O)CO
• Isomeric SMILES: CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)CO
• Recent ClinicalTrials: Topical Anti-Androgens in Pilonidal Sinus Disease
• Recent EU Clinical Trials: A Phase 2, multicenter, prospective, randomized, double-blind, Minoxidil and vehicle controlled, dose-ranging study to evaluate the efficacy and safety of CB-03-01 (Cortexolone 17α-propionate) solution for the treatment of androgenetic alopecia in females
• Description: Clascoterone (Winlevi?) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clascoterone for the topical treatment of acne vulgaris is unknown, the drug is believed to compete with the androgen dihydrotestosterone for binding to androgen receptors in the sebaceous gland and hair follicles to attenuate signalling necessary for acne pathogenesis. In August 2020, clascoterone cream 1% received its first approval in the USA for the topical treatment of acne vulgaris in patients 12 years of age or older. Clinical studies of a different formulation of clascoterone (a solution containing a higher concentration of the drug) for the treatment of androgenetic alopecia are underway in Germany and the USA. This article summarizes the milestones in the development of clascoterone leading to this first approval for the topical treatment of acne vulgaris.
• Uses: Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity. By competing with androgens for binding to androgen receptors, clascoterone works by blocking the androgen receptor signalling cascades that promote acne pathogenesis, such as sebaceous gland proliferation, excess sebum production, and inflammatory pathways. In August 2020, FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and female patients 12 years and older. Clascoterone is also being investigated as a novel treatment for androgenetic alopecia. Clascoterone is being developed as a topical cream by Cassiopea for androgen-?dependent skin disorders.

Technology Process of Clascoterone

There total 1 articles about Clascoterone which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 99.0%

cortexolone 17α,21-dipropionate (19608-30-1) → CB-03-01 (19608-29-8)

Guidance literature:

With butan-1-ol; Candida cylindracea lipase; In toluene; at 30 ℃; for 24h; Product distribution / selectivity; Enzymatic reaction;

upstream raw materials:

cortexolone 17α,21-dipropionate

Refernces

• 1、 Ferraboschi, Patrizia,Mieri, Maria De,Ragonesi, Laura. "Lipase-catalyzed preparation of corticosteroid 17α-esters endowed with antiandrogenic activity". . p. 4610 - 4612. Retrieved 2008/09/21.